Conversation with The Cancer Letter FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done May 06, 2022Vol.48 No.18By Matthew Bin Han Ong
Regulatory News Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand May 06, 2022Vol.48 No.18By Alice Tracey
Capitol Hill Whither ARPA-H? What can Biden’s agency do that cancer centers can’t? May 06, 2022Vol.48 No.18By Paul Goldberg
Guest Editorial Let’s learn from our neighbors from the North as we get the menthol flavor out of cigarettes May 06, 2022Vol.48 No.18By David Balis
Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing April 29, 2022Vol.48 No.17By Alice Tracey
Regulatory News FDA’s Brian Booth: “We need to reconsider our approach to dose selection” April 29, 2022Vol.48 No.17By Alice Tracey
LGBTQ+ Cancer Symposium aims to increase visibility of patients of all genders and sexualities April 29, 2022Vol.48 No.17By Alice Tracey
Regulatory News As part of Cancer Moonshot, FDA seeks to prohibit menthol cigarettes, flavored cigars April 29, 2022Vol.48 No.17By Paul Goldberg
FreeIn the Archives Recent contributors: Duke, Sarah Cannon, and the UA Center for the Study of Tobacco and Society April 29, 2022Vol.48 No.17
